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Class I  major histocompatibility complex (MHC) ~ antigens (HLA-A,B,C and 
/32m  [/~-microglobulin])  are  expressed  on  most  nucleated  human  cells,  with 
neurons  and  the  mature  trophoblast  being  the  principal  exceptions  (1,  2). 
However, a marked deficiency in expression of these antigens has been noted in 
human  embryonal  carcinoma  (3)  and  neuroblastoma  cell  lines  (2),  as  well  as 
isolated cell  lines of lymphoid or epithelial  malignancies (4,  5).  These  studies 
have shown that human and murine cell lines devoid of surface expression  of 
Class  I  histocompatibility antigens could lack peptide  chain synthesis of either 
~2m  or  the  HLA-A,B,C  antigen,  since  cells  deficient  in  ~2m  are  unable  to 
transport HLA proteins to the cell surface. In the F9 mouse embryonal carcinoma 
line,  the  defect  in  class  I  MHC  antigens has  been  shown (6)  to  be  a  marked 
reduction  in  H-2  and /32m mRNA transcription,  which could be  increased by 
incubating the ceils in retinoic acid. 
Because these molecules play an  important role in  immune cell recognition, 
the  low or absent  expression  of HLA-A,B,C antigens in  malignant tissues has 
been viewed with great interest for its implications in tumor growth and metas- 
tasis. In addition, rat cells transformed by the Ela region of the highly oncogenic 
adenovirus  1 2 have diminished expression of the heavy chain of the rat class I 
MHC, which continues to be expressed in cells transformed by the nononcogenic 
adenovirus 5 (7). Thus, tumors with absent class I MHC expression may contain 
an activated Ela-like product. 
In  this paper,  we describe marked deficiencies of expression of HLA-A,B,C 
and ~2m on a panel of human small-cell lung cancer (SCLC) cell lines. In patients, 
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SCLC exhibits  rapid  growth  and  early metastases,  suggesting  resistance  to  im- 
mune control.  These deficits contrast SCLC with human lung cancers of other 
histologic  types,  including  adenocarcinoma,  epidermoid  carcinoma,  and  large- 
cell carcinoma, which  we have found  to readily express class I  antigens.  These 
results indicate an important biological difference between SCLC and non-small- 
cell lung cancer (NSCLC) cells that may be related to differences in the clinical 
and molecular biologic behavior of these two categories of human lung cancer. 
Materials and  Methods 
Cell Lines.  The  human  SCLC  lines  were  grown  in  our  laboratory in  RPMI  1640 
(Gibco Laboratories, Grand Island, NY) with  10% heat-inactivated fetal bovine serum, as 
described previously (8, 9). Cell lines derived from classic human SCLC tumors were NCI- 
H209,  H69,  H146,  H128,  H60,  H446,  and  H187.  These  cell  lines  are  distinct  by 
morphology, by a deletion of the short arm of the third chromosome, characteristic of 
SCLC (10),  by production  of bombesin and neuron-specific enolase, and  by different 
patterns of reactivity to monoclonal antibodies developed in our laboratories (11).  Bio- 
chemical and morphologic variants of SCLC included NCI-H82, H524, H526, and N417. 
Although derived from patients with SCLC, variant cell lines are characterized (12)  by 
increased growth rate and colony-forming efficiency, lack of amine precursor uptake and 
decarboxylation (APUD) markers, radioresistance, and myc amplification, in contrast to 
classic SCLC. NSCLC lines used were NCI-H23 and H125 (adenocarcinoma), NCI-H157 
(large  cell),  H292  (mucoepidermoid),  A427  (epidermoid),  and  H226  (mesothelioma). 
Other  tumor  lines  assayed  were  NCI-H78  and  H102  (malignant  T  cell)  and  H234 
(melanoma). Two B lymphoblastoid lines (H 128BL, H209BL) derived from SCLC patients 
were  also  tested.  The  SCLC,  malignant  T  cell,  and  B  lymphoblastoid lines  grew  in 
suspension. The other lines grew attached to plastic tissue culture flasks and were scraped 
off with a rubber policeman. All cells were washed with phosphate-buffered saline (PBS) 
before use. 
Monoclonal Antibodies.  Monoclonal antibody W6/32 (Accurate Chemical & Scientific 
Corp., Westbury, NY) reacts weakly with an invariant determinant on the HLA chain of 
all  HLA-A,B,C molecules and  more strongly with the  native two-chain molecule (13). 
Monoclonal antibodies H-0592 (Hybritech, Inc., La Jolla,  CA) and 9456-SA (Bethesda 
Research Laboratories, Gaithersberg, MD) also react with invariant determinants of the 
HLA-A,B,C antigen.  Monoclonal antibodies L368  (Becton Dickinson  Monoclonal Anti- 
body Center, Sunnyvale, CA), BBM.I (American Type Culture Collection), and H-0602 
(Hybritech, Inc.) react with/~m. Radiobinding assays were done at an antibody concen- 
tration of 10 #g/ml in  1% bovine serum albumin (BSA).  A conventional rabbit antisera 
specific for human ~2m was also used (Dako Corp., Santa Barbara, CA). 
Radioimmunoassay.  The radiobinding assay was performed in 96-well polyvinyl micro- 
titer ~lates (Costar, Data Packaging, Cambridge, MA). Target cells were fixed at a density 
of 10  cells per well with 0.25% glutaraldehyde and then the wells were blocked with 1% 
BSA in PBS (11).  The plates were incubated with antibody for 1 h, followed by affinity- 
purified rabbit anti-mouse hyperimmune serum for 1 h. All  incubations were in PBS at 
room temperature. The detecting reagent used was 40,000 cpm of 12~I-labeled protein A 
(sp  act,  30  uCi/ug).  Purified  mouse  myeloma  IgG2a  (RPC5;  Litton  Bionetics,  Inc., 
Kensington, MD) was used as a negative control. 
Indirect Immunofluorescence Assay.  Live cell suspensions were incubated under saturat- 
ing conditions  with  monoclonal antibodies to  HLA-A,B,C or/3~m determinants for 30 
min at room temperature, washed, and incubated with a fluoresceinated goat anti-mouse 
secondary antibody (Becton Dickinson, Monoclonal Antibody Center) for 30 min at room 
temperature. The fluorescence intensity of 2-5 x  104 cells was analyzed in an Epics V 
cell sorter (Coulter Electronics,  Inc., Hialeah FL).  Control cells  were incubated with a 
purified  mouse  myeloma IgG2A primary antibody  and  the  same  secondary antibody 
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Immunoprecipitation.  Cell  lines were labeled  metabolically for  12 h  with  [sSS]methio- 
nine  (Amersham  Corp.,  Arlington  Heights,  IL).  10  million  cells  from each  line  were 
labeled  with  1  mCi  of radionuclide.  Cell  lysates were prepared  as described  (14).  For 
immunoprecipitation, we complexed monoclonal antibodies to protein A-Sepharose and 
used this complex to immunoprecipitate the cell lysates. Normal mouse sera was used as 
a negative control for each lysate. The precipitates were displayed by electrophoresis on 
7-14% polyacrylamide gradient gels as described (15). Gels were treated  with Enhance 
(New  England  Nuclear,  Boston,  MA)  before exposure  to  Kodak  XRP  films (Eastman 
Kodak Co., Rochester, NY). The film was exposed using intensifying screens at -70°C 
for 48 h. 
Preparation and Hybridization  of Lung Cancer  Cell Line DNAs and RNAs.  Cells were 
grown as described above. DNA was prepared from each cell line and 15 ~g was digested 
with  EcoRI,  electrophoresed  on  a  0.8%  agarose  gel,  denatured,  and  transferred  to 
nitrocellulose (16). Hybridization was performed using 50% dextran sulfate (17) with the 
s2p-labeled probe and washing at 52°C (18). The HLA probe used was the human cDNA 
plasmid,  psw,  obtained  from Dr.  Sherman  Weissman (19).  The B2m probe  used  was a 
human cDNA plasmid obtained from Dr. R. Bruce Wallace (20). 
A  postnuclear supernatent  prepared  from fresh cell cultures (21) was phenol/chloro- 
form extracted and ethanol precipitated.  10 #g of total cytoplasmic RNA was denatured 
and electrophoresed on a  1% agarose-formaldebyde gel (22), that had been modified by 
using 0.22 M formaldehyde in the gel and electrophoresing at 160 V for 4 h. The gel was 
soaked in  3  M  NaCI, 0.3  M  sodium citrate.  Transfer,  hybridization, and washing were 
essentially as described for DNA. 
Interferon Induction of HLA-frame and 13~rn  Proteins.  Human recombinant leukocyte A 
interferon was supplied by Hoffmann-La Roche, Inc., Nutley,  NJ.  Its titer was 3  ×  106 
reference  units  per  milliliter,  and  its  specific activity was 6  ×  105 reference  units  per 
milligram of protein.  Human gamma interferon  (Meloy Laboratories,  Springfield,  VA) 
had a  titer  of 1  x  106  reference  units per  milliliter  and  a  specific activity of 1 ×  106 
reference units per milligram of protein. Seven SCLC lines, five NSCLC lines, and one B 
lymphoblastoid  line  were  grown  in  microtiter  dishes  at  105  cells  per  well.  Gamma 
interferon  was added  to triplicate  wells  of each  line at  concentrations of 0-104  U/ml. 
After 48 h, cells were washed three times in PBS, transferred to polyvinylchloride plates 
(Dynatech Laboratories, Inc., Alexandria, VA) and fixed with 0.25% glutaraldehyde. The 
plates were washed twice with PBS and blocked with  1% BSA. Each line was assayed at 
each interferon concentration with  10 t~g/ml monoclonal antibodies W6/32, L-368, and 
(Becton Dickinson Monoclonal Antibody Center) HLA-DR. After  1 h incubation, plates 
were washed and incubated for 1 h with 1 : 1000 dilutions of affinity-purified rabbit anti- 
mouse IgG. After washing, plates were incubated with 40,000 cpm of l~SI-protein A for 
1 h, washed, and read on a gamma counter. 
Two SCLC lines (H-209, H-146) were also grown and assayed similarly with recombi- 
nant leukocyte A interferon, with assays performed at 24, 48, 72, and 96 h after exposure 
to the  interferon.  Larger wells,  containing  106 cells per  well  of SCLC line NCI-H446, 
were assayed on an indirect immunofluorescence assay with either PBS or  104 U/ml of 
leukocyte A interferon at 24, 48, and 72 h after incubation. Indirect immunofluorescence 
assays were performed with W6/32 and L-368 as previously described. 
lmmunohistochemistry.  Malignant human tissues and cultured ceils were obtained, for- 
malin-fixed, embedded, cut, and stained as described (23). Control and interferon-treated 
cells were cytocentrifuged onto glass slides and fixed for 10 min with acetone at 4°C. The 
slides were incubated at room temperature  with either anti-HLA-A,B,C, anti-/3zm,  anti- 
HLA-DR, or control antibodies, for 45 min. After rinsing the slides, the cells were exposed 
to biotin-labeled goat anti-mouse Ig for 30 rain. The slides were incubated in methanol 
H202  solution  for  30  rain  before  the  application  of avidin-biotin-peroxidase  complex 
(ABC),  followed by diaminobenzidine-nickle  chloride-H~O2 solution  (24).  The smears 
were counterstained with methyl green. All slides were reviewed by three clinical pathol- 
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Results 
SCLC Cultured  Cell Lines Express Greatly Reduced Amounts of Surface HLA or 
132m Antigens.  Six  independent  monoclonal  antibodies  specific  for  invariant 
determinants on the class I HLA-A,B,C and ~2m proteins were tested for binding 
to SCLC, NSCLC, and non-lung cancer lines. In protein A-radiobinding assays, 
high  levels of binding  were seen with the anti-HLA antibodies to NSCLC and 
non-lung cancer lines and approached saturation at  10 ~tg/ml  antibody per  10  ~ 
target cells (Table I). In contrast, no or greatly reduced binding was noted with 
the small cell lines, depending on the antibody used. A single exception was line 
NCI-H526, an SCLC line by morphology, which consistently had high expression 
of HLA antigenic determinants,  approaching the NSCLC levels, with the three 
monoclonal  antibodies  used.  A  similar  pattern  of results  was  noted  with  the 
TABLE  I 
Binding of Monoclonal Antibodies Against HLA-A,B,C and 132m Antigens to Human Cancer 
Lines in Solid Phase Radioimmunoassay 
Binding of monoclonal antibodies 
(cpm 1251-protein A bound over background/10  s cells) against: 
HLA-A,B,C  ~-Microglobulin  Cancer Type 
W6/32  9456-SA*  H-0592  BBM.1  L-368"  H-0602" 
SCLC 
NC1-H69  0  133  394  0  0  1,216 
NCI-H146  0  589  55  0  0  624 
NCI-H209  0  362  153  0  0  484 
NCI-H60  0  38  339  0  0  627 
NCI-HI28  0  339  0  0  0  4,368 
NCI-H82  0  257  44  0  0  241 
NCI-N417  0  244  182  0  0  38l 
NCI-H 187  175  616  493  0  0  2,814 
NCI-H446  0  622  255  0  364  797 
NCI-H524  0  331  81  0  0  354 
NC1-H526  1,624  9,668  14,388  5,214  17,663  36,819 
NSCLC 
NCI-H23  1,558  13,437  19,317  3,450  18,934  36,762 
NCI-H157  4,853  13,452  16,499  8,590  23,758  35,594 
NCI-H125  1,399  13,513  18,699  3,000  22,207  33,672 
NCI-H292  191  2,780  1,910  NT  NT  21,531 
NCI-A427  NT  11,438  7,742  6,990  13,601  20,940 
NCI-H226  NT  16,490  2,465  2,018  2,401  4,916 
Other 
NCI-H234  1,190  14,357  17,624  7,248  24,005  30,786 
NCI-H 102  938  13,550  12,096  5,370  25,246  24,242 
Assays were performed using a  ~25I-protein A  assay with commercial monoclonal antibodies at a 
concentration of 10 #g/ml. Results are the average of triplicate determinations (<20%  variance 
between wells for any one test). The negative control was obtained by substituting a class-matched 
indifferent myeloma protein  for the specific monoclonal antibody.  Control radiobinding counts 
varied from  100 to 800 with the different antibodies. The numbers shown represent the cpm of 
the test well minus the cpm of the negative control. NT, not tested. 
* Monoclonal antibody assays using a rabbit anti-mouse IgG connecting antibody. DOYLE ET  AL.  1139 
monoclonal antibodies directed against ~2m, with a  strong reaction to NSCLC 
noted with three different antibodies. The 11 SCLC lines tested, with the striking 
exception of NCI-H526, were negative with two of the anti-~2m antibodies and 
slightly positive with  the other antibody,  compared with  a  control  IgG mouse 
myeloma protein.  The  ratios  of NSCLC-to-SCLC binding  of these  antibodies 
was up to 100:1  with both HLA,  A,B,C and/3~m monoclonal antibodies. 
13 SCLC and four NSCLC cell lines were tested in indirect  immunofluores- 
cence assays  for  HLA-A,B,C and  ~2nl  expression,  using  live cells,  to see if a 
subpopulation of SCLC expressed large amounts of the antigens.  While >85% 
of the  NSCLC ceils were brightly  fluorescent,  SCLC cells showed only faintly 
positive ceils.  However, this positivity was present on the large majority of the 
cells. The median fluorescence of the SCLC cells was 10-100-fold less than the 
median fluorescence of the  NSCLC cells with both HLA and/~2m  monoclonal 
antibodies (data not shown). The only overlap in fluorescence intensity between 
SCLC and NSCLC with each antibody was again seen in line NCI-H526, which 
had much greater expression  of HLA and/32m  antigens  than  any other SCLC 
line. 
Fresh SCLC Tumor Specimens Do Not Express Surface HLA-A,B,C.  To determine 
whether the loss of class I histocompatibility antigens occurred while the tumor 
was in the patient or only after cell culture, we used tumor samples taken directly 
from SCLC and NSCLC patients for immunohistochemical  staining with 9456- 
SA, a monocional antibody reactive to HLA-A,B,C. The staining of three SCLC 
samples revealed  that  uncultured  SCLC cells had  markedly  reduced  or  unde- 
tectable HLA-A,B,C expression  (data  not shown).  Similarly,  staining  of SCLC 
cells adjacent to bronchus or skin with a heteroantisera  reactive to/32m showed 
that the surrounding nonmalignant cells were positively stained with the antisera, 
but that the SCLC cells were negative (Fig.  1). 
SCLC  Cells  Synthesize  Greatly  Reduced  Amounts  of HLA-A,B,C  and  ~2m  Pro- 
teins.  To determine whether the lack of expression on the cell surface of HLA- 
A,B,C and  /3~m resulted  from a  deficiency of peptide chain  synthesis,  we per- 
formed immunoprecipitation  with antibodies directed against  HLA-A,B,C and 
/32m determinants.  We used the monocional antibody W6/32 to precipitate the 
HLA-A,B,C antigen in  12 SCLC lines and five NSCLC lines (Fig. 2). The SCLC 
lines had a marked reduction in HLA-A,B,C protein immunoprecipitated com- 
pared with the NSCLC lines, with the exception again of NCI-H526.  Densito- 
metric analysis of the SCLC HLA protein bands showed that the median SCLC 
line synthesized  1/20th the amount of HLA protein compared with the median 
NSCLC line  (Table  II).  In  the  NSCLC lines,  a  12,000  mol  wt band  was also 
noted, presumably arising from co-immunoprecipitated fl~m bound to the HLA- 
A,B,C molecule. This was not seen in any of the SCLC lines. This co-immuno- 
precipitation of fl2m has been previously described with W6/32 (25). 
To directly precipitate  ~2m,  we  used an  affinity-purified  rabbit anti-human 
/3~m heteroantiserum (this serum behaved similarly to the monoclonal antibodies 
used in the radiobinding assays described above). Using the same  12 SCLC and 
five  NSCLC  lines  as  in  the  HLA  immunoprecipitation,  we  found  a  marked 
reduction in the  12,000 tool wt/32m bands precipitated in SCLC compared with 
NSCLC (Fig.  3).  Densitometry analysis showed the median  value of the SCLC 1 140  LACK  OF  HLA  ANTIGENS  IN  SMALL-CELL  LUNG  CANCER 
FIGURE  1.  Photomicrographs of SCLC invading lung parenchyma in vivo. (A) After immu- 
nohistochemical staining with rabbit anti-/J2m, pulmonary alveolar cells (left) show  marked 
immunoreactivity as opposed to the unstained tumor (right). (B) A serial section, 50 #m apart, 
stained with routine hematoxylin and eosin. The alveoli (left) contain cellular debris; SCLC is 
seen on the right. 
t32m  bands  to  be  1/10th  of the  median  NSCLC  value (Table  II).  Of interest  is 
the  abnormally  high  molecular  weight  of the  13~m band  seen  in  NCI-H446,  a 
SCLC line (Fig. 3). 
SCLC  Cells  Contain  Markedly  Reduced  Levels  of  HLA-A,B,C  and  132m 
mRNAs.  Knowing  that  the  diminished cell surface  expression  of class  I  MHC 1141 
FIGURE 2.  Immunoprecipitation analysis of HLA-A,B,C in lung cancer cell lines. [ssS]Methi- 
onine-labeled  SCLC and NSCLC lysates were incubated with an anti-HLA-A,B,C monoclonal 
antibody in an immunoprecipitation  assay. The HLA-A,B,C antigen band is at 45,000 tool wt, 
coprecipitated/3~m is at 12,000 rnol wt. Lanes b through m are SCLC cell lysates immunopre- 
cipitated with the antibody; n through q are NSCLC cell lysates. (a) Molecular weight standard; 
(b) NCI-H60; (c) NCI-H69; (d)  NCI-H82; (e) NCI-HI28; Q-) NCI-H146; (g) NCI-H187; (h) 
NC1-H209; (i) NC1-H372; (j) NCI-H417; (k) NCI-H446; (l) NCI-H524; (m) NCI-H526; (n) 
NCI-H23; (0) NC1-H 125; (p) NCI-H 157; (q) NCI-A427; (r) NCI-H 128 BL (B lymphoblastoid). 
antigens was correlated with greatly reduced immunoprecipitable peptide chains, 
we next investigated class I  MHC mRNA production.  We analyzed RNA blots 
from  12 well-characterized  human  lung cancers with  molecularly cloned HLA 
and  /32m cDNA probes.  The  HLA cDNA probe used (psw) corresponds to an 
HLA-B locus alloantigen (19), and detects a single RNA band of ~ 1,400 nucleo- 
tides. When  NSCLC total cellular  RNA was probed with psw, a  single distinct 
band of 1.4 kilobase (kb) was seen (Fig. 4).  Of the  10 SCLC lines tested, several 
failed to give a  positive signal,  and  most gave a  faint positive signal  only after 
prolonged exposure of the gel. Densitometric analysis indicated that the median 
density  of the  SCLC  HLA  mRNA  binds  was  less  than  one-fifth  that  of the 
NSCLC values (Table II). As a positive control, we used a B lymphoblastoid line 
(NCI-HI28 BL) derived from the same patient as the NCI-H128 SCLC line; it 
showed a strong, single,  1.4 kg HLA mRNA band. 
The  /3~m cDNA probe  used detects a  single  RNA band  of 620  nucleotides 
(20). Using the same cell lines as in the psw assay, we found a 0.6 kb band in the 
B  lymphoblastoid and  lung adenocarcinoma  lines (Fig.  5).  The  10  SCLC lines 
tested showed positive but reduced signals with median densitometric/~2m mRNA 
levels less than  one fifth of the NSCLC values (Table II). The SCLC line NCI- 
H526 was again the exception, with levels of HLA and/32m mRNA comparable 
to  the  NSCLC  levels,  correlating  with  its  increased  HLA  and  /32m protein 
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TABLE  II 
Relative Amounts of HLA-A,B,C and [32m Protein and mRNA Bands in SCLC and NSCLC 
Percent  Percent  Percent/~m  Percent B2m  Cell line  HLA RNA  HLA protein  RNA  protein 
SCLC 
NCI-H372  NT  1  8  10 
NCI-H 146  1  5  I  16 
NC1-H209  NT  1  NT  8 
NCI-H128  2  3  12  15 
NCI-H60  NT  2  NT  9 
NCI-H417  5  2  8  11 
NCI-H187  7  9  8  24 
NCI-H82  NT  1  NT  24 
NCI-H249  9  NT  22  NT 
NC1-H446  NT  4  NT  31 
NCI-H69  10  6  18  11 
NCI-H524  12  2  8  29 
NCI-H231  15  NT  22  NT 
NC1-H526  65  24  53  55 
NSCLC 
NCI-H23  27  6  38  17 
NC1-H125  66  34  58  131 
NCI-H 157  NT  47  NT  90 
NCI-A427  NT  24  NT  20 
B Lymphocyte 
NCI-H128 BL  100  100  100  100 
Assays were performed using radioautograms developed on Kodak XRP film. Results compare the 
relative densities of HLA  and ¢3~m RNA and protein bands in  SCLC  and NSCLC  cell lines after 
standard immunoprecipitation and Northern blotting procedures. Relative densities were compared 
as percentages of the density of NCI-H 128 BL, an Epstein-Barr virus-transformed B lymphoblastoid 
line derived from a SCLC patient. Densitometry measurements were performed on a DU-8 densitom- 
eter (Beckman Instruments, Inc., Fullerton, CA). NT, not tested. 
FIGURE 3.  Immunoprecipitation analysis of/32m  in lung cancer cell lines.  [sSS]Methionine- 
labeled  SCLC  and  NSCLC  lysates  were  incubated with  an  anti-fl~m heteroantisera  in  an 
immunoprecipitation assay. The 132m antigen band is at 12,000 mol wt. Lanes b through m are 
SCLC cell lysates immunoprecipitated with the antisera; n through q are NSCLC cell lysates. 
(a) Molecular weight standard; (b) NCI-H60; (c)  NCI-H69; (d) NCI-H82;  (e) NCI-H128;  (.D 
NCI-HI46;  (g) NCI-HI87;  (h) NC1-H209;  (i) NCI-H372;  (j) NC1-H417;  (k) NCI-H446;  (l) 
NCI-H524; (m) NCI-H526;  (n) NCl-H23;  (o) NCI-H125;  (p) NCI-HI57;  (q)  NCI-A427; (r) 
NCI-H 128 BL (B lymphoblastoid). DOYLE  ET  AL.  1143 
FIGURE 4.  Northern blot analysis of RNA prepared from fresh cell cultures. 10 #g of total 
cytoplasmic RNA was denatured and electrophoresed on a 1% agarose-formaldehyde  gel. The 
HLA probe was a human cDNA plasmid, psw, which hybridizes to a single 1.4 kb RNA band. 
Radioautography was performed with a 96 h exposure. (A) Lambda HindIIl-digested  genornic 
DNA; (B) NCI-N417 (SCLC-v); (C) NCI-H128  BL (immortalized lymphob|astoid line); (D) 
NC1-H 128 (SCLC); (E) NCI-H 146 (SCLC); (F) NCI-H69 (SCLC); (G) NCI-H23 (NSCLC). 
FIGURE 5.  Northern blot analysis of RNA prepared from fresh cell cultures. 10 #g of total 
cytoplasmic RNA was denatured and electrophoresed on a 1% agarose-formaldehyde  gel. The 
/3~m probe was  a  human  cDNA  fragment that  hybridizes to a  single 0.6  kb  RNA band. 
Radioautography was performed with a 96 h exposure. (a) NCI-H 187 (SCLC); (b) NCI-H231 
(SCLC);  (c)  NCI-H524 (SCLC-v);  (d) NCI-N417  (SCLC-v); (e) NCI-H69  (SCLC);  (f)  NC1- 
H249 (SCLC); (g) NCI-H23 (NSCLC); (h) NCI-H125 (NSCLC); (i) NCI-H128 BL (B lympho- 
blastoid). 
HLA  and  132m Genes  Are  Present  in  SCLC.  Because  of  decreased  mRNA 
production  we next asked if deletion or rearrangement  of class I  antigen genes 
had  taken  place.  We  analyzed  EcoRI-digested genomic  DNA  from  eight  well- 
characterized human  lung cancer cell lines with the HLA  and/32m cDNA probes, 
using the Southern  nitrocellulose transfer method  (16).  The  polymorphic band- 1144  LACK  OF  HLA  ANTIGENS  IN  SMALL-CELL  LUNG  CANCER 
ing pattern detected by the psw probe in the SCLC lines was similar to the signals 
detected with the NSCLC and control cell line lanes (data not shown). The DNA 
banding  pattern  detected with  the  /32m probe  was  identical  in  the  SCLC and 
NSCLC lines (data not shown). 
Interferon  Induces Increased Expression of Surface HLA-A,B,C and/32m Antigens 
in SCLC Cells.  Interferon has been shown to increase HLA and/32m expression 
in several systems (26, 27). SCLC cells were incubated with interferon and the 
class  I  MHC  antigen  expression  was  monitored.  Recombinant  leukocyte  A 
interferon increased the expression of HLA-A,B,C and/32m surface antigens in 
radiobinding  (Fig.  6) and indirect  immunofluorescence assays (Fig.  7).  Gamma 
interferon  also increased /~2m expression  3-50-fold and  increased  HLA-A,B,C 
antigen 2-24-fold (Table III). In contrast, interferon had no effect on HLA-DR 
expression,  which  remained  low  (data  not  shown).  The  expression  of both 
antigens  increased  with  increasing  doses up  to  104  U/ml  of both gamma  and 
recombinant leukocyte A interferons.  The effect of both gamma and leukocyte 
A interferons in all assays was complete at 24 h and was not appreciably altered 
between 24 and  96 h.  In addition both interferons also increased  HLA-A,B,C 
and 132m expression on the several NSCLC lines and the B lymphoblastoid line 
tested.  In  indirect  immunofluorescence  assays with SCLC line  NCI-H446,  the 
number of antigen-positive cells increased; also, fluorescence increased >10-fold 
in both HLA-A,B,C and/32m assays after incubation with  104 U/ml of recombi- 
nant  leukocyte A  interferon,  compared  with  treatment  with  the  PBS control 
(Fig. 7). 
The SCLC line NCI-H69 was used for immunohistochemical  staining with an 
anti-HLA monoclonal antibody before and after interferon treatment (data not 
shown). The anti-HLA antibody was minimally reactive to NCI-H69 cells without 
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FIGURE 6.  Radiobinding assay using W6/32, a monoclonal antibody reactive to HLA-A,B,C, 
and L-368, a monoclonal antibody reactive to B~m, to determine expression of these antigens 
on two SCLC lines (NCI-H209 and NCI-H 146) after incubation with varying concentrations 
of recombinant leukocyte A interferon. Interferon was added in triplicate to wells of each line 
at concentrations of 0-104 U/ml. After 24 h, cells were fixed with glutaraldehyde and assayed 
with the monoclonal antibodies. Plates were sequentially incubated with an affinity-purified 
rabbit anti-mouse IgG antiserum and 125I-labeled protein A, and the wells were counted on a 








t  t 
j  I 
?o  lOO 
LOG FLUORESCENCE 
1.20 
~  0.80 
0.40 
,~  o 
B 
/  I 
t  i 
i  i 
i  i 
'~ /  ', 
°\1 
i 
~ t I/ 
10  100 
LOG FLUORESCENCE 
10~0 
FIGURE 7.  Positive HLA-A,B,C and/32m fluorescence in SCLC line NCI-H446 after inter- 
feron incubation. Cells were incubated with either PBS or 104 U/ml of recombinant leukocyte 
A interferon. After 24 b, the live cell suspensions were incubated with a monoclonal antibody 
to HLA-A,B,C (A) or to/32m determinants (B). Cells were then incubated with a fluuorescein- 
ated goat anti-mouse secondary antibody. Fluorescence was analyzed in a Coulter Epics V cell 
sorter. The NSCLC line NCI-H 157  was used, without interferon pretreatment as a positive 
control in each case. 
TABLE  III 
Induction  of HLA-A,B,C and ~2m Antigens by Interferon in SCLC 
Cell Lines 
Cell line 
Fold induction of: 
HLA-A,B,C  /32m 
NCI-H60  4  17 
NCI-H69  10  51 
NCI-H 128  18  34 
NCI-H 146  24  5 
NCI-HI87  2  3 
NCI-H209  14  12 
NCI-H417  3  23 
Assays were performed on SCLC cells incubated at  I0  ~ cells per well in 
microtiter wells with  104  U/ml of gamma interferon for 48  h. Control 
wells with no interferon were prepared for each cell line. After 48 h, cells 
were washed with PBS and fixed to polyvinylchloride plates with 0.25% 
glutaraldehyde. The plates were reacted with 50 #1  of W6/32  (reactive 
with HLA-A,B,C) or L-368 (reactive with/32m).  Both antibodies were at a 
concentration  of 10 tzg/ml. The plates were washed, then serially incubated 
with affinity-purified rabbit anti-mouse lgG and ~2~I-labeled staphylococ- 
cal protein A. Counts were read on a gamma counter. Results represent 
the mean number of counts for each cell line after interferon incubation 
divided by the mean number of counts of the control wells. 
interferon  treatment but became markedly positive after 48 h  exposure to  104 
U/ml of gamma interferon  incubation.  In contrast,  control immunoperoxidase 
staining  with  a  monoclonal  antibody  reactive  to  HLA-DR remained  negative 
after interferon incubation (data not shown). 
Discussion 
We have demonstrated  that  SCLC cells express greatly reduced amounts  of 
class I cell surface antigens, their immunoprecipitable proteins, and their corre- 1 146  LACK  OF  HLA  ANTIGENS  IN  SMALL-CELL  LUNG  CANCER 
sponding  mRNAs, but have apparently  intact  class I  MHC genes, indicating  a 
block of mRNA transcription.  In  this  respect,  SCLC cells clearly  differ  from 
NSCLC  cells  in  class  I  MHC  antigens.  Both  SCLC  and  NSCLC  have  low 
expression of class II  HLA-DR antigens,  as demonstrated  by protein  A  radio- 
binding and indirect immunofluorescence assays (data not shown). 
Including this report, three classes of human carcinomas have been shown to 
have  frequent  deficits of class  I  MHC antigen  expression:  germ  cell  cancers, 
neuroblastoma,  and now, small-cell  lung cancer.  The recently described HLA- 
A,B,C deficiencies in neuroblastoma are particularly interesting since they extend 
the  biochemical  similarities  noted  between  adrenergic  neuroblastomas  and 
SCLC.  Both  of these  tumors  produce  L-dopa decarboxylase (8),  have  similar 
patterns of reactivity to monoclonal antibodies developed in our laboratory (1 1, 
29), and have similar cell surface protein phenotypes (30). The markedly reduced 
surface expression of class I MHC peptides in both cell types raises the question 
of whether other normal and malignant  APUD cells lack HLA-A,B,C and ¢/2m 
expression. However, neuroblastoma cell lines produce/32m while displaying no 
detectable HLA-A,B,C antigen (2), whereas SCLC lines appear to have deficien- 
cies of both HLA framework and/32m proteins (though the/32m deficiency may 
be less marked than  the HLA-A,B,C loss).  There is a reproducible spectrum in 
the degree of HLA-A,B,C deficiency in the SCLC lines with a roughly parallel 
decrease  in  internal  132m peptide.  While  small  amounts  of 132m proteins  are 
translated in all SCLC cell lines, the absence of intracellular HLA-A,B,C protein 
may prevent 13em from getting to the cell surface, explaining the more striking 
deficiency of 132m protein by radiobinding assays. Alternatively, an altered form 
of internal/32m peptide, as seen in NCI-H446, may not be transported to the cell 
surface.  SCLC  is  unique  among  human  tumor  lines  in  having  deficiencies of 
expression  of both class  I  chains:  the  germ  cell  tumors and  occasional breast, 
colon, and lymphoma lines with class I MHC deficiencies all appear to lack only 
one of the two antigens.  In the Daudi Burkitt's lymphoma line (31), the inability 
to  produce  ~2m  may  be associated  with  major  deletions  on  chromosome  15, 
where the/32m gene is located (31). Karyotyping of multiple SCLC lines (10) has 
not shown any obvious abnormalities of chromosomes 15 or 6, where the human 
class I MHC genes are located. 
The closest parallel to the loss of both HLA-A,B,C and/32m antigens in SCLC 
lines appears to be the F9 mouse teratocarcinoma line. This line has been shown 
to have an RNA transcription block of both class I MHC antigens (6). Of interest, 
F9 cells have been shown to have a  surface glycoprotein identified as the stage- 
specific embryonic antigen (SSEA) (32, 33). SSEA is found in the early embryo 
and disappears at the same developmental stage that H-2 MHC antigens appear 
(34). The majority of SCLC lines have a  dominant  carbohydrate antigen  lacto- 
N-fucopentose III (LNFP3), which is identical to the determinant recognized by 
monoclonal antibodies made against SSEA (35). However, using [35S]methionine- 
labeled SCLC cells, we have so far been unable to immunoprecipitate a protein 
with 534-F8, a monoclonal anti-SCLC antibody reactive to LNFP3 (35). The F9 
teratocarcinoma line has been shown to differentiate with retinoic acid treatment 
(36), and differentiated clones were found to express H-2 and/3em antigens but 
to have  lost  SSEA expression  (36).  In  contrast,  treatment  of SCLC cells with 
recombinant  leukocyte A  interferon  did  not  cause  a  reduction  in  their  high DOYLE  ET  AL.  1147 
reactivity to  534-F8 after  induction  of HLA-A,B,C and 132m peptide synthesis 
(data not shown). 
Interferons have been found to augment expression of class I  MHC antigen 
expression in melanoma cells (26), and have been shown to induce mRNA for 
MHC antigens in human fibroblasts and lymphoblastoid cells (27). The current 
experiments,  however, represent  the  first reported  example  of interferons  in- 
creasing the RNA transcription of class I MHC antigens that had been markedly 
diminished.  There is a presumed role for interferon in increasing HLA expres- 
sion, as part of the immune response of a virally infected host, for the elimination 
of HLA-matched  infected cells.  Increased  HLA expression  in SCLC might  be 
expected to facilitate the destruction of cells bearing tumor-associated antigens. 
With 25,000 cases of SCLC diagnosed in the United States every year, SCLC 
is  the  most common  human  malignancy  associated with  major  deficiencies of 
class I antigens. As a tumor that can be grown in cell culture with high efficiency 
it is a valuable model for studies on human histocompatibility antigen expression. 
Our results also raise a basic clinical question. A growing body of literature (37- 
39) suggests that class II MHC antigens participate in the lysis of tumor cells by 
cytotoxic T  lymphocytes. It has been suggested (40) that a  lack of HLA-A,B,C 
may offer a growth advantage to tumors with weak expression of the molecules. 
Studies with  melanoma  line  variants  that  were low in  class  I  MHC expression 
(41)  showed  that  these  variants  were  more  likely  to  metastasize  from  locally 
implanted mouse tumors than were lines high in MHC expression. In this context 
we note  that  SCLC  is  clinically  characterized  by aggressive  growth  and  early 
metastasis.  Since  NSCLC (which  requires  different  treatment  than  SCLC) ex- 
presses both  HLA-A,B,C  and  ¢/2m antigens,  these  markers  are  of immediate 
diagnostic  value  in  tumor  typing.  Administering  interferon  to  SCLC patients 
after  their  tumor  bulk  had  been  reduced  by chemotherapy  and  radiotherapy 
could be of value in delaying or preventing tumor recurrence. 
The mechanism of decreased class I MHC mRNA transcription  in SCLC cells 
is unknown, but may be comparable to the decrease in histocompability antigen 
transcription  seen in rat cells after malignant  transformation  by the Ela region 
of adenovirus strain  12 (7). The small-cell variant lines have been shown to have 
an amplification of the c-myc oncogene (12) which,  like Ela, appears to have an 
establishment function in cell transformation  (42). Cell lines of neuroblastoma, 
the other non-germ cell tumor with consistent decreases in class I MHC antigen 
expression, also have amplification  of a  c-myc-related oncogene, N-myc (43).  In 
general,  the  SCLC  lines  with  the  greatest  amplification  of c-myc also had  the 
lowest measurable levels of class I histocompatibility antigens.  Of interest, NCI- 
H23,  a  lung  adenocarcinoma  line  amplified  for c-myc, had  significantly  lower 
amounts of HLA-A,B,C protein and mRNA than the other NSCLC lines tested. 
Decreased transcription  of class  I  MHC message may be a  common aspect of 
malignant  transformation  with the functional class of oncogenes that include, c- 
myc, N-myc, and E la. 
Summary 
We have found markedly deficient expression of the class I major histocom- 
patibility antigens HLA-A,B,C and t32m on human small-cell lung cancer (SCLC) 
lines and fresh tumor samples. The deficit of HLA-A,B,C and/32-microglobulin 1148  LACK OF  HLA  ANTIGENS  IN  SMALL-CELL LUNG  CANCER 
(/~2m) antigen expression was  demonstrated  with both radiobinding assays and 
indirect  immunofluorescence assays.  Immunoprecipitation  of metabolically la- 
beled cells with antibodies to class  I  antigens  showed most SCLC lines to have 
synthesized  almost  no  /~2m and  HLA-A,B,C  proteins.  Northern  blot  analysis, 
using human  HLA-A,B, and/3zm cDNA probes,  showed that almost all SCLC 
lines tested had markedly decreased amounts of HLA and/3~m mRNA, but both 
gene products could be induced with interferon treatment  of SCLC lines.  We 
conclude that human SCLC, in contrast to other lung cancer types, is character- 
ized  by  greatly  reduced  transcription  of HLA-A,B,C  and  /32m genes,  which 
suggests the existence of a mechanism for evading the host immune response to 
the tumor and of an Ela-like product in this type of tumor cell. 
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